NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nurix Therapeutics Inc (NRIX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments in its clinical pipeline and analyst ratings are favorable, the stock lacks immediate catalysts, and technical indicators do not suggest a strong entry point. Additionally, financial performance, while improving, remains negative. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this investment for now is recommended.
The MACD histogram is negative and contracting (-0.129), RSI is neutral at 38.467, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level (16.094), with support at 15.402 and resistance at 16.785. Overall, the technical indicators do not suggest a strong buy signal.
Analyst ratings are consistently positive, with multiple firms raising price targets and maintaining Buy or Overweight ratings. The company's pipeline, particularly the bexobrutideg trials, shows promise for long-term growth.
No significant news or event-driven catalysts in the short term. The stock lacks immediate clinical or financial triggers to drive momentum. Additionally, financials remain negative, with a net loss of -$78.22M in Q4 2025.
In Q4 2025, revenue increased by 2.21% YoY to $13.58M, net income improved by 33.60% YoY but remains negative at -$78.22M, and EPS rose by 9.33% YoY to -$0.82. Gross margin remains at 100%. While there is improvement, the company is still not profitable.
Analysts are bullish, with multiple firms raising price targets recently (ranging from $29 to $36) and maintaining Buy or Overweight ratings. However, key catalysts for the stock are expected in the second half of 2026 and beyond, making it a longer-term play.
